Newsquawk Logo

Moderna (MRNA) announces US FDA will initiate review of its investigational seasonal influenza vaccine submission; FDA assigned a prescription drug user fee act goal date of August 5th, 2026

Moderna's FDA submission review for its seasonal influenza vaccine is a notable development in the biotechnology space, indicating progress in diversifying its vaccine portfolio.

Newsquawk StaffPublished On the live feed at — 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Riksbank Governor Bunge says recent cyclical indicators have been mixed, developments are in line with forecasts

Ukraine and China plan ministry level meetings; Ukraine interested in leaders-level dialogue with China, Tykhyi reports

Moderna (MRNA) announces US FDA will initiate review of its investigational seasonal influenza vaccine submission; FDA assigned a prescription drug user fee act goal date of August 5th, 2026

Analog Devices Inc. (ADI) (Q1 2026): Adj. EPS 2.46 (exp. 2.31), Revenue 3.16bln (exp. 3.11bln), Q2 adj. EPS view 2.88 (exp. 2.46), revenue view 3.5bln (exp. 3.24bln)

Moody's Corporation (MCO) Q4 2025 (USD): Adj. EPS 3.64 (exp. 3.43), Revenue 1.9bln (exp. 1.86bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

With a PDUFA goal date set for August 5, 2026, investors should monitor not just the approval process but also how this aligns with the company's overall strategic direction and revenue potential in a competitive market.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.